Effect of statin therapy on restenosis after coronary stent implantation

The effect of statins on the development of restenosis and clinical outcome after coronary stent implantation was assessed in a retrospective analysis of 525 consecutive patients. Baseline clinical, angiographic, and procedural characteristics did not differ between 258 patients with and 267 patients without statin therapy. Statin therapy was associated with a significantly (p <0.04) improved survival free of myocardial infarction and a significant reduction in repeat target vessel revascularization procedures (27.9% vs 36.7%, p <0.05) during 6-month follow-up. Minimal lumen diameter was significantly larger (1.98 ± 0.88 vs 1.78 ± 0.88 mm, p = 0.01), late lumen loss was significantly less (0.64 ± 0.8 vs 0.8 ± 0.8 mm, p = 0.032), and net gain significantly increased (1.2 ± 0.88 vs 0.98 ± 0.92 mm, p = 0.009) in patients receiving statin therapy. Dichotomous angiographic restenosis (≥50%) rates were significantly lower, with 25.4% in the statin group compared with 38% in the no-statin group (p <0.005). Multivariate analysis identified statin therapy (p = 0.005), minimal lumen diameter immediately after stenting (p = 0.02), and stent length (p = 0.02) as independent predictors for subsequent restenosis development. Thus, statin therapy is associated with reduced recurrence rates and improved clinical outcome after coronary stent implantation.